[
    [
        {
            "time": "",
            "original_text": "西南证券给予华大基因持有评级，新冠检测需求驱动2020年业绩大增，常规业务逐步恢复",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠检测",
                    "业绩大增",
                    "常规业务恢复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券给予华大基因持有评级，新冠检测需求驱动2020年业绩大增，常规业务逐步恢复",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "西南证券：华大基因（300676.SZ）新冠检测需求驱动2020年业绩大增，维持“持有”评级",
            "features": {
                "keywords": [
                    "华大基因",
                    "新冠检测",
                    "业绩大增",
                    "持有评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券：华大基因（300676.SZ）新冠检测需求驱动2020年业绩大增，维持“持有”评级",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "电鳗快报|福兮祸所依！华大基因年报净利润激增6倍 多项费用及信用减值损失也同步大增",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利润激增",
                    "费用增加",
                    "信用减值损失"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "电鳗快报|福兮祸所依！华大基因年报净利润激增6倍 多项费用及信用减值损失也同步大增",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]